Moderna Reports Q4 With Revenue Cratering 35% as the mRNA Pioneer's Cancer Vaccine Pipeline Becomes Its Only Path to Long-Term Relevance
Moderna reports Q4 2025 earnings on February 13 with analysts expecting a $2.64 per share loss and revenue declining 35% year over year as COVID vaccine demand collapses and the company pivots to cancer immunotherapy.